Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
Open Access
- 1 December 1987
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 24 (6) , 827-829
- https://doi.org/10.1111/j.1365-2125.1987.tb03254.x
Abstract
The possibility of simplifying the regimen for the collection of urine samples in the determination of the debrisoquine metabolic ratio (DMR) was explored in 15 normal subjects. In the extensive metaboliser subgroup (EM; n = 11), there was a close correlation between the DMR as determined by an 8 h urine collection and the debrisoquine/4- hydroxydebrisoquine ratio (D/4-OHD) in the hourly samples (excluding the first hour). In the poor metabolisers (PM; n = 4) the phenotype could be identified, but it was not possible to estimate the DMR reliably.This publication has 18 references indexed in Scilit:
- Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosusArthritis & Rheumatism, 1986
- The Polymorphic Oxidation of ??-Adrenoceptor AntagonistsClinical Pharmacokinetics, 1986
- ECOGENETICS OF PARKINSON'S DISEASE: 4-HYDROXYLATION OF DEBRISOQUINEThe Lancet, 1985
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Metabolic oxidation phenotypes as markers for susceptibility to lung cancerNature, 1984
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Some observations on the oxidation phenotype status of Nigerian patients presenting with cancerCancer Letters, 1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Why hypertensive patients vary in their response to oral debrisoquine.BMJ, 1977